Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for ...

Upstream Bio Inc. UPB shares are up on Thursday following the company’s announcement of a Phase 3 development strategy for ...

ROME, Feb 4 (Reuters) - Italy's economy is ‌estimated to grow by 0.7% both this ‌year and next, the parliamentary budget watchdog UPB said on Wednesday, upgrading its 2026 estimate and slightly ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

Upstream Bio (UPB) saw its shares move slightly in recent trading, which has caught the attention of investors keen to track shifts in the biotech sector. The company’s stock has gained 7% over the ...

Shares of inflammatory disease biotech Upstream Bio, Inc. (UPB) have rallied by roughly 60% since reporting potentially best-in-class data for its asset verekitug in a Phase 2 trial in early September ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

The latest price target for Upstream Bio (NASDAQ:UPB) was reported by Evercore ISI Group on November 18, 2025. The analyst firm set a price target for $40.00 expecting UPB to rise to within 12 months ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.